Home / Stocks / MET

MetLife (MET, Life & Health Insurance) Stock Valuation & Fair Value Fairly valued

MetLife (MET, Life & Health Insurance) trades at a blended P/E of 9.8 — about 3% above its historical normal valuation — with a forward growth estimate of 11.4% and a PEG of 0.85. Analysts' one-year estimates have been hit 27% of the time.

DATA AS OF 2026-07-14
Blended P/E
9.8
Normal P/E
9.5
PEG
0.85
Fwd growth
11.4%
Div yield
2.6%

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-06-03.

2026-06-03P/E 8.9-7%Fairly valued
2026-06-10P/E 9.1-4%Fairly valued
2026-06-14P/E 9.1-4%Fairly valued
2026-06-16P/E 9.1-4%Fairly valued
2026-06-21P/E 9.1-4%Fairly valued
2026-07-02P/E 9.3-2%Fairly valued
2026-07-06P/E 9.6+1%Fairly valued
2026-07-09P/E 9.6+1%Fairly valued
2026-07-12P/E 9.8+3%Fairly valued
2026-07-13P/E 9.8+3%Fairly valued
2026-07-14P/E 9.8+3%Fairly valued ← now

Frequently asked questions

Is MetLife stock overvalued?

At a blended P/E of 9.8 versus its historical normal P/E of 9.5, MetLife trades about 3% above its typical valuation, with a PEG of 0.85 on 11.4% forward growth — tickerseer currently rates it fairly valued.

What is MetLife's fair value and PEG?

MetLife trades at a blended P/E of 9.8 against a historical normal P/E of 9.5, a PEG of 0.85, and a forward growth estimate of 11.4%.

Has tickerseer's rating of MetLife changed?

tickerseer's rating has been fairly valued since 2026-06-03.

Industry: Life & Health Insurance. Create a free account to unlock the full analysis — the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track MET free — valuation & earnings alerts